Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 December 2005, Vol. 106, No. 12, pp. 3917-3925.
Prepublished online as a Blood First Edition Paper on August 16, 2005; DOI 10.1182/blood-2005-04-1424.


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-04-1424v1
106/12/3917    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kerbauy, D. M
Right arrow Articles by Deeg, H J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kerbauy, D. M
Right arrow Articles by Deeg, H J
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted April 7, 2005
Accepted July 25, 2005

NF-{kappa}B and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDS)

Daniella M Kerbauy, Vladimir Lesnikov, Nissa Abbasi, Sudeshna Seal, Bart Scott, and H J Deeg*

Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Fred Hutchinson Cancer Research Center, Seattle, WA, USA; University of Washington School of Medicine, Seattle, WA, USA

* Corresponding author; email: jdeeg{at}fhcrc.org; blarson@fhcrc.org.

Tumor necrosis factor (TNF)-{alpha}, a potent stimulus of NF-{kappa}B, is upregulated in myelodysplasia (MDS). Here, we show that bone marrow mononuclear cells (BMMC) and purified CD34+ cells from patients with low grade/early stage MDS (RA/RARS) have low levels of NF-{kappa}B activity in nuclear extracts comparable to normal marrow, while patients with RA with excess blasts (RAEB) show significantly increased levels of activity (P=0.008). Exogenous TNF-{alpha} enhanced NF-{kappa}B nuclear translocation in MDS BMMC above baseline levels. Treatment with arsenic trioxide (ATO; 2-200 µM) inhibited NF-{kappa}B activity in normal marrow, primary MDS, and ML1 cells, even in the presence of exogenous TNF-{alpha} (20 ng/mL), and downregulated NF-{kappa}B-dependent anti-apoptotic proteins, Bcl-XL, Bcl-2, XIAP, and FLIP, leading to apoptosis. However, overexpression of FLIP resulted in increased NF-{kappa}B activity and rendered ML1 cells resistant to ATO-induced apoptosis. These data are consistent with the observed upregulation of FLIP and resistance to apoptosis with advanced MDS where ATO as a single agent may show only limited efficacy. However, the data also suggest that combinations of ATO with agents that interfere with other pathways, such as FLIP autoamplification via NF-{kappa}B, may have considerable therapeutic activity.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
A. J. Mhyre, A. M. Marcondes, E. Y. Spaulding, and H. J. Deeg
Stroma-dependent apoptosis in clonal hematopoietic precursors correlates with expression of PYCARD
Blood, January 15, 2009; 113(3): 649 - 658.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Dolniak, E. Katsoulidis, N. Carayol, J. K. Altman, A. J. Redig, M. S. Tallman, T. Ueda, R. Watanabe-Fukunaga, R. Fukunaga, and L. C. Platanias
Regulation of Arsenic Trioxide-induced Cellular Responses by Mnk1 and Mnk2
J. Biol. Chem., May 2, 2008; 283(18): 12034 - 12042.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. M. Marcondes, A. J. Mhyre, D. L. Stirewalt, S.-H. Kim, C. A. Dinarello, and H. J. Deeg
Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function
PNAS, February 26, 2008; 105(8): 2865 - 2870.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. C. Bornhauser, L. Bonapace, D. Lindholm, R. Martinez, G. Cario, M. Schrappe, F. K. Niggli, B. W. Schafer, and J.-P. Bourquin
Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway
Blood, September 15, 2007; 110(6): 2084 - 2091.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
D. Cilloni, G. Martinelli, F. Messa, M. Baccarani, and G. Saglio
Nuclear factor {kappa}B as a target for new drug development in myeloid malignancies
Haematologica, September 1, 2007; 92(9): 1224 - 1229.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Kannan-Thulasiraman, E. Katsoulidis, M. S. Tallman, J. S. C. Arthur, and L. C. Platanias
Activation of the Mitogen- and Stress-activated Kinase 1 by Arsenic Trioxide
J. Biol. Chem., August 11, 2006; 281(32): 22446 - 22452.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T.-C. Lee, I-C. Ho, W.-J. Lu, and J.-d. Huang
Enhanced Expression of Multidrug resistance-associated Protein 2 and Reduced Expression of Aquaglyceroporin 3 in an Arsenic-resistant Human Cell Line
J. Biol. Chem., July 7, 2006; 281(27): 18401 - 18407.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020